Extended Data Fig. 10. Toxicity assay results and body weight measurements of mice treated with PARP inhibitors (PARPi) and ALK inhibitors.
(a) Panels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine in mice bearing PARPi-resistant tumors. Mice were treated with oral talazoparib (0.33 mg/kg) and lorlatinib (5 mg/kg), either alone or in combination, five times per week. (b, c) Body weight of mice bearing PARPi-resistant tumors. Mice were treated with oral talazoparib (0.33 mg/kg) and lorlatinib (5 mg/kg), either alone or in combination, five times per week (b), or with oral olaparib (50 mg/kg) and ceritinib (7.5 mg/kg), either alone or in combination, five times per week (c). N = 5 mice were used in each treatment group. Error bars represent the mean ± SD. Statistical analysis was carried out using the two-way ANOVA analysis with no statistical significance specified as n.s.